Skip to main content

Sara Isabel Reidel

Institutions of which they are part

Research technician
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Sara Isabel Reidel

Institutions of which they are part

Research technician
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

ERN-EuroBloodNet: EUROPEAN REFERENCE NETWORK ON RARE HEMATOLOGICAL DISEASES

IP: M Mar Mañu Pereira
Collaborators: María de los Ángeles Rodríguez Sánchez, Reidel , Sara Isabel, Claire Diot, Victoria Gutierrez Valle, Sara Isabel Reidel
Funding agency: EUROPEAN COMMISSION
Funding: 371825
Reference: EUROBLOODNETBR2022_EU4H-ERN2022
Duration: 01/05/2022 - 30/11/2023

IMPACT- AML

IP: M Mar Mañu Pereira
Collaborators: Ali Haidar, Reidel , Sara Isabel, Sara Isabel Reidel
Funding agency: EUROPEAN COMMISSION
Funding: 253750
Reference: IMPACT-AML_HE--MISS-CANCER2022
Duration: 01/04/2023 - 31/03/2028

SYNTHEMA: Synthetic generation of hematological data over federated computing frameworks

IP: M Mar Mañu Pereira
Collaborators: Reidel , Sara Isabel, Ali Haidar, Sara Isabel Reidel
Funding agency: EUROPEAN COMMISSION
Funding: 435938
Reference: SYNTHEMA_HE-HLTH22_IND13
Duration: 01/12/2022 - 30/11/2026

GENOMED4ALL - Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases

IP: M Mar Mañu Pereira
Collaborators: Reidel , Sara Isabel, Ali Haidar, Ferran Balbastre Ubeda, Amira Idrizovic, Sara Isabel Reidel
Funding agency: EUROPEAN COMMISSION
Funding: 434000
Reference: GENOMED4ALL_H2020-SC1-FA-DTS-2018-20
Duration: 01/01/2021 - 31/12/2024

Related news

"Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Related professionals

Yassin Belahnech Pujol

Yassin Belahnech Pujol

Postdoctoral researcher
Cardiovascular Diseases
Read more
Marc Rivas Agudo

Marc Rivas Agudo

Research technician
Diabetes and Metabolism
Read more
Anna  Pascual  Carreño

Anna Pascual Carreño

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Meritxell Ventura Cots

Meritxell Ventura Cots

Main researcher
Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.